In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

ISAR-TEST-4 study: Randomized trial of 3-limus agent-eluting stents with biodegradable or permanent polymer coating

Hot Line II

Acute Coronary Syndromes (ACS)

Read the press release

Presenter | see Discussant report

Julinda Mehili (Germany)

Presentation webcast

Presentation slides 

List of Authors:

J. Mehilli, A. Kastrati, R.A. Byrne, S. Kufner, S. Massberg, K.A. Birkmeier, K-L. Laugwitz, S. Schulz, J. Pache, M. Fusaro, M. Seyfarth, A. Schömig


Discussant | see Presenter abstract

Aaron Kugelmass (United States of America)

presentation webcast

presentation slides


Dr.Mehilli and colleagues are to be congratulated on the ISAR-TEST-4 trial. The study of over 2600 patients is the largest randomized trial of a biodegradable polymer based DES to date.

The study population is comparatively “non-idealized”, and reflects real world practice with both stable angina and acute coronary syndrome patients. The population mirrors that of contemporary practice both clinically, (patients with diabetes, prior infarction and/or multivessel disease), and angiographically, (mean vessel size of 2.8 mm and greater than 70% B2 or C lesions).

Current DES, which have durably reduced clinical and angiographic restenosis, utilize permanent polymers. It is thought that these polymers contribute to hypersensitivity reactions, ongoing inflammation, and thrombogenicity. Thus, current polymers likely contribute to delayed angiographic and clinical events such as late lumen creep, and delayed restenosis and stent thrombosis. Thus, the appeal of DES utilizing a biodegradable polymer.


At both 30 days and twelve months, the biodegradable polymer stent was significantly non-inferior to available limus stents for both safety (cardiac death/MI) and clinical restenosis (TLR). Each of the contributing endpoints appeared similar. This is encouraging, but begets the question as to what is the appropriate clinical and angiographic surveillance period for biodegradable polymer stents. As is evident from DES, attempts to reduce vascular inflammation can result in temporal shifts in angiographic and clinical sequellae. Will the results of biodegradable polymer stents prove as durable as current DES? Hopefully ISAR-TEST-4 includes longer term clinical and angiographic follow up. With additional follow up, this data can help drive this promising technology.




Randomized trial of 3-limus agent-eluting stents with biodegradable or permanent polymer coating. ISAR-TEST-4 study

Notes to editor

This congress report accompanies a presentation given at the ESC Congress 2009. Written by the author himself/herself, this report does not necessarily reflect the opinion of the European Society of Cardiology.

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.